For laboratory research use only. Not for human consumption. Sold by Explicit SARMs solely as reference material for in-vitro and animal research by qualified professionals. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
BPC-157 and TB-500 are two of the most frequently paired peptides in research catalogs, and a pre-combined vial raises practical questions that single-peptide products don’t. This FAQ covers what is in the blend, how each component is described in the literature, and what to check before the material goes into a study.
What is in the BPC-157 / TB-500 blend?
Each vial contains equal amounts of the two peptides by mass. The BPC-157 / TB-500 Blend 10mg contains 5 mg of BPC-157 and 5 mg of TB-500. The BPC-157 / TB-500 Blend 20mg contains 10 mg of each.
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide whose sequence is a partial fragment of a protein originally isolated from gastric juice, often called “body protection compound.” Its published literature is almost entirely preclinical, made up of cell and rodent studies, and a large share of it comes from a single research group. That concentration is worth keeping in mind when weighing how well a finding has been replicated.
What is TB-500?
TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein that regulates actin, the main structural protein of the cell cytoskeleton. The two names are often used interchangeably in catalogs, but they are not the same molecule. TB-500 is a fragment, and thymosin beta-4 is the full-length protein. Studies on one do not automatically describe the other.
Why are the two studied together?
The two peptides are proposed to act through different mechanisms. BPC-157 is most often discussed in connection with angiogenesis and growth-factor signaling, and thymosin beta-4 with actin dynamics and cell migration. That difference is why researchers interested in tissue-repair models sometimes look at them side by side. Published work on the combination itself is far thinner than work on either peptide alone. A study using the blend should include single-peptide arms if the goal is to attribute an effect to either component.
Should I use the blend or the individual peptides?
It depends on the design. A fixed 1:1 blend simplifies preparation when that exact ratio is what the protocol calls for. Separate vials of BPC-157 and TB-500 let you vary the ratio, run single-agent controls and track lot numbers for each peptide independently.
Do you provide a certificate of analysis?
Yes. A COA is available on request through our contact page, and our products are purity-tested by an independent third-party lab. For a blend, check that the COA identifies both peptides, not just the total peptide content.
How should the lyophilized powder be handled?
Keep vials sealed and protected from moisture and light until use. Reconstitute only what the experiment needs, using a solvent appropriate to your method. Bacteriostatic water is a common laboratory choice. Record the lot number and reconstitution date for every vial.
Is the blend approved for human use?
No. Neither BPC-157 nor TB-500 is approved by the FDA or any other regulator for any indication, and both appear on the World Anti-Doping Agency’s prohibited list: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (peptide hormones, growth factors and related substances). The blend is sold strictly as research material, and we do not provide dosing, administration or usage guidance.